Skip to main content
SpringerLink
Log in

Adverse outcomes with direct-acting antivirals for HCV infections

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. McGlynn EA, et al. Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C. JAMA Network Open : 7 Jun 2019. Available from: URL: http://dx.doi.org/10.1001/jamanetworkopen.2019.4765

  2. Beste LA. Concerns About Direct-Acting Antiviral Agents for Hepatitis C - Cause for Reassurance. JAMA Network Open : 7 Jun 2019. Available from: URL: http://dx.doi.org/10.1001/jamanetworkopen.2019.4757

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adverse outcomes with direct-acting antivirals for HCV infections. Reactions Weekly 1758, 4 (2019). https://doi.org/10.1007/s40278-019-63550-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-63550-5

Search

Navigation